Suzano (SUZB3) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
13 Aug, 2026Executive summary
Adjusted EBITDA reached R$4.7 billion in Q2 2026, up from R$4.6 billion in Q1 2026 but down from R$6.1 billion in Q2 2025, driven by higher prices and stronger volumes.
Free cash flow was R$3.3 billion, a significant increase from R$0.6 billion in Q1 2026 and 27% higher than Q2 2025, supported by working capital release and lower capex.
Net income was R$1.8 billion, a 58% drop from Q1 2026 and 64% lower year-over-year, reflecting weaker financial results and higher costs.
Successfully closed the Arbex acquisition (51% stake in a global tissue JV with Kimberly-Clark) for US$1.3 billion on July 1, 2026, with integration and efficiency gains underway.
Leadership transition in industrial operations, with Carlos Aníbal assuming the EVP role.
Financial highlights
Net revenue for Q2 2026 was R$11.6 billion, up 6% sequentially but down 13% year-over-year, mainly due to lower pulp sales and FX impacts.
Adjusted EBITDA margin was 41% in Q2 2026, down 5 p.p. year-over-year.
Net debt decreased to US$12.8 billion from US$13.0 billion in Q1 2026, with leverage at 3.4x.
Liquidity stood at US$6.9 billion, improving from US$6.1 billion in Q1 2026.
Positive cash adjustments from FX and oil hedges totaled BRL 480 million and BRL 150 million, respectively.
Outlook and guidance
Pulp business expects stronger sales in the second half of 2026 due to favorable seasonality and higher production availability.
2026 cash cost guidance remains on track at approximately R$800/ton, with further reductions anticipated in H2.
Net debt and leverage targets in US$ (US$11.0 billion and <2.5x) expected to be achieved in 2027–2028.
Arbex integration is a focus for value creation and efficiency gains in H2 2026.
Standalone Consumer Goods segment will be disclosed from 3Q26 onwards.
Latest events from Suzano
- Strong financials, cost discipline, and sustainability drive growth and diversification.SUZB3
Conference presentation - Pulp sales and prices up YoY, but profit and EBITDA fell; major tissue deal to close mid-2026.SUZB3
Q1 2026 - Record sales, strong EBITDA, and major acquisition highlight robust 2025 performance.SUZB3
Q4 2025 - Adjusted EBITDA dropped 20% YoY to R$5.2bn as lower pulp prices offset efficiency gains.SUZB3
Q3 2025 - Strong sales growth, robust cash flow, and major strategic moves marked the quarter.SUZB3
Q2 2025 - Net revenue and EBITDA surged on higher sales and FX gains, with leverage and liquidity improving.SUZB3
Q3 2024 - EBITDA up 60% YoY to R$6.3B, but net loss of R$3.8B on FX and derivative impacts.SUZB3
Q2 2024 - Net income surged to R$6.3B in 1Q25, driven by strong sales, FX gains, and cost discipline.SUZB3
Q1 2025 - Record sales and EBITDA growth from new mill and acquisitions, despite net loss on FX impacts.SUZB3
Q4 2024